Sepsis is a syndrome comprised of a systemic inflammatory response, signs of tissue
hypoperfusion, and organ in the setting of presumed infection. Heparin, in addition to being
an anticoagulant, is also a well-known antiinflammatory. The investigators believe that
unfractionated heparin has the potential to save the lives of septic patients at a
drastically reduced cost. This is a dose escalation study to determine the safety of
increasing levels of heparin in this patient population; compare markers of anticoagulation
and inflammation between treatment groups; and compare clinical outcomes between groups.